In a recent genome-wide association study (GWAS) of 57,800 subjects from multiple asthma cohorts, the minor T allele of the IL-6 receptor (IL6R) single nucleotide polymorphism (SNP) rs4129267 (1q21.3) was identified as a novel asthma susceptibility locus (odds ratio, 1.09) in subjects of European ancestry.
1 This SNP was not evaluated for associated asthma severity phenotypes, including lung function, in this GWAS, but this SNP has been associated with differences in pulmonary function in healthy subjects from the Framingham Heart Study. 2 The SNP rs4129267 is located in intron 8 of IL6R and is in linkage disequilibrium (LD; r 2 5 1) with the IL6R coding SNP rs2228145 (Asp 358 Ala). The Ala 358 variation modifies the IL-6R peptide structure adjacent to the exterior cell surface and significantly enhances proteolytic cleavage of IL-6R from cell surfaces into the extracellular space, which is termed IL-6R ''shedding.'' 3, 4 IL-6R shedding is increased in subjects who inherit the IL6R rs2228145 C allele (Ala 358 ) and is easily measured in serum. 5 The soluble IL-6 receptor (sIL-6R) can be activated by IL-6 and can form a complex with the ubiquitously expressed membrane-bound glycoprotein 130, resulting in activation of the IL-6 signal transduction pathway in cells that do not express membrane-bound IL-6R. This dysfunctional activation of IL-6 signaling is termed IL-6 transsignaling. 6 During IL-6 transsignaling, the sIL-6R/glycoprotein 130 complex induces tyrosine kinase Janus kinase 2 activity, which phosphorylates and activates the transcription factor signal transducer and activator of transcription 3. Activated signal transducer and activator of transcription 3 translocates to the nucleus to affect a wide range of gene expression. IL-6 transsignaling has been implicated in a range of inflammatory diseases, including rheumatoid arthritis, 7 Crohn disease, 8 and inflammatory bowel disease, 9 and is the target of anti-IL-6R therapies. Supported by grants HL69116, HL69130, HL69155, HL69167, HL69170, HL69174,  HL69349, HL091762, HL087665, HL101487, KL2RR025009, M01 RR02635, M01  RR03186, M01 RR007122-14, 1UL1RR024153, 1UL1RR024989, 1UL1RR024992,  1UL1RR025008, 1UL1RR025011 , and U01 HL56899, and the Children's Healthcare of Atlanta Center for Developmental Lung Biology.
In this study the IL6R coding SNP rs2228145 (Asp 358 Ala) was evaluated in subjects of European white ancestry in 2 asthma cohorts to determine whether the coding variation is associated with lung function, an important asthma severity phenotype. Because of the wide range of lung function in the Severe Asthma Research Program (SARP) cohort, the IL6R coding SNP was first evaluated in the SARP cohort. 11 Lung function associations were then verified in the Collaborative Study on the Genetics of Asthma (CSGA) cohort and in a combined analysis of the SARP and CSGA cohorts. Because this coding SNP is associated with elevated serum levels of sIL-6R, SARP subjects were evaluated to determine whether correlations exist between serum sIL-6R and lung function in subjects who inherit the IL6R Ala 358 isoform. The IL6R coding SNP was also evaluated in SARP phenotypic asthma clusters 12 to evaluate potential associations with more severe asthma. Immunohistochemistry was used to evaluate lung biopsy specimens and bronchial alveolar lavage (BAL) cells to determine whether lung cells express IL-6R protein and thus possible sources for IL-6R shedding. Finally, BAL fluid was evaluated in a small subset of SARP subjects to determine whether increased BAL sIL-6R levels were associated with inheriting the IL6R Ala 358 isoform.
METHODS

Subject recruitment
Subjects of European ancestry from 9 clinical research centers that comprise the National Heart, Lung, and Blood Institute-sponsored SARP study were characterized with spirometry and were phenotyped using comprehensive standardized approaches, as previously described. 11, 12 Current smokers and subjects with more than 5 pack years of smoking were ineligible for this study. In brief, subjects were defined as having severe asthma using the American Thoracic Society (ATS) workshop criteria for refractory asthma. 13 For comparison, additional subjects with nonsevere asthma were studied who did not meet the ATS workshop criteria. After appropriate withholding of bronchodilators, spirometry was performed according to ATS guidelines. 14 Hankinson values were used to calculate percent predicted FEV 1 . 15 Subjects were required to have a percent predicted FEV 1 of greater than 55% to qualify for testing for bronchial responsiveness to methacholine (PC 20 ). 11 Bronchodilator reversibility was tested using a maximal protocol of up to 8 puffs of albuterol.
This study was approved by the institutional review boards at all study sites, and all patients provided informed consent to participate in this study. The replication population consisted of subjects of European ancestry from the Collaborative Study of the Genetics of Asthma at Wake Forest School of Medicine. 16, 17 These subjects were studied using a similar protocol to SARP for phenotypic characterization.
11 SARP control subjects used for serum analysis had no history of asthma and no first-degree relatives with asthma.
SNP genotyping and assessment
All IL6R genotypes were acquired from the Illumina Human1M-Duo DNA BeadChip (Illumina, San Diego, Calif) from our previous GWAS. 18 In addition to primary analysis of rs2228145, the 9 additional IL6R SNPs rs6427641, rs1386821, rs6684439, rs4845618, rs8192282, rs4845371, rs4129267, rs4240872, and rs2229238 were selected for analysis based on LD (r 2 ) values from the HapMap database (http://hapmap.ncbi.nlm.nih.gov/). The genotyping efficiency on the Illumina Human1M-Duo DNA BeadChip for all IL6R SNPs was greater than 99%, and all SNPs were in HardyWeinberg equilibrium.
Serology and immunohistochemistry
Investigative bronchoscopy was performed on a subset of SARP subjects with all levels of asthma severity.
11 All subjects undergoing bronchoscopy were self-selected for this portion of the SARP study, and biopsy specimens analyzed were randomly selected without a priori selection based on asthma severity. Endobronchial biopsy specimens (n 5 14) from formalin-fixed, paraffin-embedded sections (5 mm) were deparaffinized (Histoclear II; National Diagnostics, Atlanta, Ga) and rehydrated through decreasing ethanol solutions. The airway tissue was treated for antigen retrieval (Dako, Glostrup, Denmark) and blocked before incubation steps with primary IL-6Ra mAb (specific to Arg387-Arg468; R&D Systems, Minneapolis, Minn), secondary biotin-labeled anti-mouse immunoglobulin (GE Healthcare, Fairfield, Conn), streptavidin-alkaline phosphatase (Roche, Mannheim, Germany), and development with Vector Red substrate (Vector Laboratories, Burlingame, Calif). Sections were counterstained with Mayer hematoxylin.
BAL cells (n 5 22) were air-dried on cytospin slides, fixed with 10% formalin for 15 minutes, and washed once with PBS before storage at 2208C. BAL cells were randomly selected from subjects who had undergone bronchoscopy, and the subset of cells was analyzed without a priori selection based on asthma severity. Cells were blocked with 100% FBS in PBS with 0.1% saponin, avidin, and biotin separately (Vector Blocking Kit) before incubation with primary IL-6Ra mAb (R&D Systems), secondary biotin-labeled anti-mouse immunoglobulin (GE Healthcare), streptavidin-alkaline phosphatase (Roche), and development with BCIP/NBT substrate (Dako) containing a 1:100 dilution of levamisole (Sigma, St Louis, Mo).
Serum and BAL sIL-6R levels were measured with the sIL-6R DuoSet (R&D Systems) ELISA kit and reported in ng/mL. All serum samples were diluted 1:200.
Statistical analysis
Analysis was performed by using a linear additive model adjusting for the age and sex for each population and in a combined dataset for the asthma quantitative traits percent predicted FEV 1 (ppFEV 1 ), percent predicted forced vital capacity (ppFVC), FEV 1 /FVC ratio, and PC 20 using ANOVA (2-tailed P values), as implemented in SAS/Genetics software (SAS Institute, Inc, Cary, NC). Serum sIL-6R measurements were analyzed using a general linear model and were log transformed to normalize sample distribution.
RESULTS
Study population characteristics
The demographic characteristics of SARP subjects with asthma in this study are described in Table I and recently have recently been extensively reported. 11 DNA from subjects of European white ancestry with asthma (n 5 510, 44% with severe asthma) and without asthma (n 5 45) were genotyped. Subjects with severe asthma met the ATS criteria for severe asthma and were all treated with high-dose inhaled or oral corticosteroids at recruitment, whereas 60% of subjects with nonsevere asthma were treated with inhaled corticosteroids. Spirometry was performed after withholding short-acting bronchodilators for 6 hours and long-acting bronchodilators for 12 hours. The characteristics of subjects from the CSGA population (Table I) have been previously described in detail and consisted of subjects of European ancestry with a spectrum of asthma severity (n 5 239).
16,17
IL6R SNP rs2228145 is associated with lung function and hyperresponsiveness
Genotypes for the IL6R SNPs rs4129267 and rs2228145 were available from the same GWAS, 18 and these 2 SNPs are in complete LD (r 2 5 1). Because lower lung function is an important phenotype for asthma, 13 we first evaluated the SNP rs2228145 for association with lung function in the SARP cohort, replicated independently in CSGA, and then investigated these phenotypes in a combined cohort analysis (SARP plus CSGA, Table II ). After adjusting for age of enrollment and sex, the C allele of rs2228145 was associated with lower percent predicted FEV 1 , lower percent predicted FVC, and a lower FEV 1 /FVC ratio in the SARP cohort. In the CSGA cohort the C allele of rs2228145 was associated with lower percent predicted FEV 1 . In a combined cohort analysis (SARP plus CSGA), the rs2228145 C allele was associated with lower percent predicted FEV 1 , lower percent predicted FVC, and a lower FEV 1 /FVC ratio. In the combined analysis subjects who were homozygous for the rs2228145 C allele (Ala 358 ) had the lowest mean percent predicted FEV 1 (71.90%), lowest percent predicted FVC (84.23%), and lowest FEV 1 /FVC ratio (0.69). Bronchial hyperresponsiveness (PC 20 ) was not significantly associated with rs2228145 in the SARP cohort; however, the rs2228145 C allele (Ala 358 ) was associated with methacholine responsiveness in the CSGA and combined cohort analyses.
After evaluation of rs2228145, additional IL6R SNPs available on the Illumina 1 M Duo chip were evaluated. The results for the combined cohort analysis are shown in Table E1 in this article's Online Repository at www.jacionline.org. In addition to rs2228145, several additional IL6R SNPs were associated with percent predicted FEV 1 , percent predicted FVC, FEV 1 /FVC ratio, and PC 20 .
IL6R SNP rs2228145 is associated with severe asthma clusters
The SNP rs2228145 was further evaluated in phenotypic severity clusters recently described for the SARP cohort. 12 SARP clusters 1 (mild asthma), 2 (moderate asthma), and 4 plus 5 (severe asthma) were evaluated. A fifth cluster (cluster 3) representing a moderate-to-severe phenotype with late-onset asthma was not used in this analysis to better define the severity classes. The rs2228145 C allele was most frequent (0.48) in the combined 4 plus 5 SARP cluster (P 5 .003, Table III) . A secondary analysis comparing rs2228145 CC genotype frequency versus AA1AC genotype frequency showed that subjects with the rs2228145 CC genotype (Ala 358 /Ala 358 ) were more frequent in the SARP 4 plus 5 cluster (frequency 5 0.29) compared with the mean frequency among all 4 clusters (frequency 5 0.20, Fig 1) .
Serum sIL-6R levels are elevated in severe asthma clusters and associated with lung function Serum sIL-6R levels were measured in 146 SARP subjects of European ancestry with asthma (40 with severe asthma) and 46 control subjects. Standard curves measuring sIL-6R or sIL-6R saturated with IL-6 were not significantly different (r 2 > 0.95), indicating that IL-6 did not alter the specificity of the anti-sIL-6R antibody in the ELISA. The IL6R mutation Ala 358 was strongly associated with elevated sIL-6R levels in subjects with asthma (P < 10
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; Fig 2, A) and those without asthma (P < .0001, data not shown). There was no significant difference in mean sIL-6R serum levels between subjects with asthma (Log sIL-6R 5 1.64 6 0.14) and control subjects (Log sIL-6R 5 1.61 6 0.18). In subjects with asthma, elevated serum sIL-6R levels were associated with lower percent predicted FEV 1 (P 5 .02) and percent predicted FVC (P 5 .008; Fig 2, B and C, respectively) . Serum sIL-6R levels were significantly higher in the SARP 4 plus 5 cluster (P 5.016, Table III ). The combined SARP 4 plus 5 cluster also had the lowest mean percent predicted FEV 1 (54.3%). There was no association between serum sIL-6R levels and lung function in healthy subjects.
IL-6R protein is expressed in BAL and lung epithelial cells
Endobronchial biopsy specimens (n 5 14) and BAL cells (n 5 22) from subjects with asthma were immunostained with an mAb specific for membrane-bound IL-6Ra (Arg387-Arg468) to determine whether IL-6R protein was expressed in the lung. IL-6R staining was observed in the airway epithelium in all samples. Additional IL-6R was observed in vascular endothelium, airway smooth muscle, and some individual cells in the submucosa. A representative stained endobronchial biopsy specimen is shown in Fig 3, A. In BAL cells (Fig 3, B) , IL-6Ra staining was observed predominantly in macrophages, although some polymorphonucleated granulocytes showed lower amounts of IL-6Ra expression (Fig 3, B, upper right) . Lack of BAL cell permeabilization during antibody incubation steps reduced specific IL-6Ra immunostaining intensity, indicating that the intracellular portion of IL-6R was targeted by this antibody.
BAL fluid was evaluated in 16 subjects with asthma. The highest levels of BAL sIL-6R were observed in subjects with the rs2228145 CC genotype (Ala 358 /Ala 358 ; Log sIL-6R 5 2.1 6 0.12; n 5 4) compared with those seen in subjects with the AA genotype (Asp ; Log sIL-6R 5 1.8 6 0.09; n 5 4); however, the trend was not statistically significant. 
DISCUSSION
In this study we have identified the IL6R coding SNP rs2228145 (Asp 358 Ala) as a potential genetic modifier of lung function in subjects with asthma and as a potential novel genetic marker of asthma severity. In separate and combined analyses of the SARP and CSGA European ancestry asthma cohorts, the minor C allele of rs2228145 (Ala 358 ) was consistently associated with lower percent predicted FEV 1 and lower FEV 1 /FVC ratio and the highest level of methacholine responsiveness. In addition, the the rs2228145 C allele frequency was found to be higher in SARP phenotypic asthma clusters consisting of subjects with more severe asthma. We have also shown, for the first time, that copious IL-6R protein is expressed in multiple cell types in the lung.
These observations are important in light of the recent GWAS of approximately 58,000 subjects that identified IL6R as an asthma risk gene.
1 In this GWAS a single IL6R SNP (rs4129267) was identified as conferring asthma risk. Because of the small sizes of the SARP and CSGA cohorts used in this study, we were not able to replicate the asthma risk assessment performed in the large GWAS. In addition, direct comparison of the data from this study with the large GWAS was not possible because the GWAS did not evaluate lung function and presented no information on the proportion of subjects with severe asthma.
Because our genotyping data were derived from the Illumina Human1M-Duo DNA BeadChip, additional IL6R SNP genotypes, including the risk SNP rs4129267, could be analyzed. We were thus able to show that rs4129267 was a tagging SNP (r 2 5 1) for the coding SNP rs2228145 (Asp 358 Ala). We were also able to show that additional IL6R SNPs were associated with lung function, including the SNP rs4129267 from the original GWAS. However, the SNP rs2228145 was the only nonsynonymous coding change genotyped in our study and is the only known IL6R SNP that affects IL-6R protein function. On the basis of our observations and the strong LD between rs2228145 and rs4129267, we propose that the coding SNP rs2228145 is most probably the genetic variant conferring asthma risk in the large asthma GWAS.
In a random subset of SARP subjects, the rs2228145 C allele (Ala 358 ) was strongly associated with increased serum sIL-6R levels, which is consistent with previous observations. 5 However, we did not observe a statistically significant difference in serum sIL-6R levels between subjects with asthma and unaffected control subjects, as has been reported in a smaller sampling of Japanese subjects (n 5 38). 19 The discrepancy between our results and the Japanese study could be explained by ethnic differences; however, this discrepancy is most likely the result of the smaller sample size used in the Japanese study.
An important advantage of this current study was the use of the SARP cohort. SARP consists of an asthma cohort enriched for severe asthma and, unlike other asthma cohorts, has subjects with a wide range of lung function and extensive phenotypic characterization that are complemented with comprehensive genetic studies. 11, 12 The extensive phenotypes collected in the SARP cohort 11 have allowed the development of phenotypic asthma clusters 12 that better describe asthma heterogeneity and severity. Because the IL6R Ala 358 variant occurred at a higher frequency in the severe asthma clusters, subjects in these clusters might be important in evaluating the long-term effects of the IL6R coding SNP rs2228145 (Asp 358 Ala), perhaps providing one reason why subjects in asthma clusters 4 and 5 have lower lung function and more severe asthma. SARP is a cross-sectional study that is currently evolving into a longitudinal cohort, and thus we will be able to determine whether our IL6R observations can be used to predict changes in lung function over time. Unfortunately, we are not aware of other well-characterized asthma cohorts with longitudinal data and a wide range of lung function in which these data can be replicated.
On the basis of our observations and reports linking IL-6 transsignaling to other inflammatory diseases, such as inflammatory bowel disease 9 and rheumatoid arthritis, 7 we propose that IL-6 transsignaling also has a pathogenic effect in the lung. The immunochemistry data from this study show that membranebound IL-6R is expressed in both BAL cells and lung epithelial cells, providing ample sources of IL-6R shedding in the lung that can be associated with increased bronchial inflammation. During inflammation, concurrent increases in IL-6 and IL-6R shedding would create an optimal environment for increased IL-6 transsignaling. 7 In subjects with mild episodic asthma, the pathologic effects of IL-6 transsignaling would be short lived because IL-6 levels return to normal when lung inflammation resolves. In subjects with more severe asthma and persistent bronchial inflammation, chronically increased IL-6 levels in the lung could sustain IL-6 transsignaling in the presence of high levels of sIL-6R. The pathogenic effects of short-term and longterm IL-6 transsignaling in the lung have not been investigated.
The identification of the IL6R coding SNP rs2228145 (Asp 358 Ala) as a risk variant for lower lung function indicates that dysfunctional IL-6 transsignaling might be a potentially important therapeutic target in subjects with severe asthma. Currently, therapies targeting IL-6 transsignaling are under development for treating several inflammatory diseases, 8, 10, [20] [21] [22] [23] [24] and the results of this study might serve as the focus for the evaluation of this therapeutic class of drug in subjects with severe asthma. In the absence of a clinical genetic test for the IL6R mutation (Asp 358 Ala), it is possible that increased serum sIL-6R levels might be a surrogate biomarker to identify subjects at risk for more severe asthma and who might benefit from anti-IL-6R therapy. 
